Welcome to NanoViricides Blog!

NanoViricides Presents at the MicroCap Conference 2025

SHELTON, CT / ACCESS Newswire / January 29, 2025

NanoViricides, Inc. (NYSE American:NNVC), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, is proud to announce its presentation at the MicroCap Conference 2025 in Atlantic City, NJ. The event will take place on Wednesday, January 29, 2025, from 11:00 am to 11:30 am at The Borgata Hotel.

NanoViricides is on the path towards Phase II Safety, Tolerability, and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease.

The event is open to everyone, and we welcome you to join us for this exciting presentation.

How This Will Affect You?

As a potential patient, the development of NanoViricides’ antiviral drugs could mean a breakthrough in treatment options for viral diseases like MPOX. The Phase II evaluation of NV-387 brings hope for more effective and targeted therapies, potentially improving outcomes and quality of life for those affected by such diseases.

How This Will Affect the World?

The advancements made by NanoViricides in developing broad-spectrum antiviral drugs have the potential to impact global health significantly. By creating drugs that viruses cannot escape, the Company is paving the way for more robust responses to viral outbreaks and pandemics, ultimately contributing to a healthier world population.

Conclusion

In conclusion, NanoViricides’ presentation at the MicroCap Conference 2025 marks a significant milestone in the development of revolutionary antiviral drugs. The Company’s dedication to advancing treatments for viral diseases is inspiring, and we look forward to the positive impact their research will have on individuals and communities worldwide.